Biotech Deal Volume Increases 58% in Q3:16

Overall, mergers and acquisitions slowed in Q3:16, down 11% compared with Q2:16, and 10% lower than in Q3:15. The biotechnology sector saw just the opposite phenomenon. Biotech transactions grew by 58%, to 52 deals, compared with the previous quarter’s 33 deals, and by 24% compared with the same quarter in 2015, when 42 deals were […]

Allergan Is Bullish on Biotech

Ever since Allergan (NYSE: AGN) completed the $40.5 billion sale of its generics business to Teva Pharmaceutical Industries (NYSE: TEVA) on August 2, the pharma giant is targeting biotech companies with a vengeance. In September alone (and we’re only talking about three weeks at this point), the company has announced four deals, totalling $1.28 billion. Year-to-date, Allergan has announced […]